Over the past year, OMass has made meaningful progress across its portfolio, including advancing our lead MC2 antagonist towards the clinic, establishing in vivo efficacy for our first-in-class ...

New research shows that after the body's defenses kill the virus behind COVID-19, leftover digested chunks of SARS-CoV-2 ...

Implants like stents, stent grafts and replacement heart valves often combine ePTFE (expanded polytetrafluoroethylene) with ...

Apecotrep (BI 764198) is a potential first-in-class, oral, selective TRPC6 inhibitor being investigated as a novel, targeted, non-immunosuppressive therapy in people with primary focal segmental ...

We often think we know more than we actually do. While four in five Americans consider themselves knowledgeable about the ...

Researchers at University of Tsukuba and their collaborators have demonstrated that learning from both rewarding and aversive ...

Allergic diseases represent a major global health burden, placing significant strain on health care systems worldwide. Severe ...

Key takeawaysA UCLA-led research team demonstrated that when human immune enzymes break up the spike protein of the virus ...

UCLA scientists have developed advanced miniature 3D tumor organoid models that make it possible to study glioblastoma tumors in a setting that closely mirrors the human brain, shedding light on how ...

Nectins and Nectin-like (Necl) proteins are immunoglobulin-like adhesion molecules involved in cell–cell contact, synapse organization, and tissue ...

Not intended for the UK Apecotrep (BI 764198) is a potential first-in-class, oral, selective TRPC6 inhibitor being investigated as a novel, targeted, non-immunosuppressive therapy in people with prima ...

Infectious diseases are illnesses caused by pathogenic microorganisms—including viruses, bacteria, fungi, and parasites—that invade a host, replicate, and ...